AHX Stock Overview
Apiam Animal Health Limited, a vertically integrated animal health company, provides veterinary products and services to production and companion animals in Australia.
Apiam Animal Health Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||AU$0.73|
|52 Week High||AU$0.99|
|52 Week Low||AU$0.63|
|1 Month Change||-9.26%|
|3 Month Change||7.30%|
|1 Year Change||-24.62%|
|3 Year Change||53.13%|
|5 Year Change||-8.13%|
|Change since IPO||-41.67%|
Recent News & Updates
Apiam Animal Health (ASX:AHX) Has Announced That Its Dividend Will Be Reduced To A$0.004
Apiam Animal Health Limited ( ASX:AHX ) is reducing its dividend to A$0.004 on the 21st of Octoberwhich is 67% less...
|AHX||AU Healthcare||AU Market|
Return vs Industry: AHX underperformed the Australian Healthcare industry which returned -19.9% over the past year.
Return vs Market: AHX underperformed the Australian Market which returned -9.7% over the past year.
|AHX Average Weekly Movement||5.2%|
|Healthcare Industry Average Movement||5.2%|
|Market Average Movement||9.6%|
|10% most volatile stocks in AU Market||16.9%|
|10% least volatile stocks in AU Market||4.3%|
Stable Share Price: AHX is less volatile than 75% of Australian stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: AHX's weekly volatility (5%) has been stable over the past year.
About the Company
Apiam Animal Health Limited, a vertically integrated animal health company, provides veterinary products and services to production and companion animals in Australia. The company operates through three segments: Dairy and Mixed, Feedlots, and Pigs. It engages in the provision of veterinary wholesale, diagnostics laboratories, custom vaccines, logistics, and other ancillary services.
Apiam Animal Health Fundamentals Summary
|AHX fundamental statistics|
Is AHX overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|AHX income statement (TTM)|
|Cost of Revenue||AU$125.09m|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||0.027|
|Net Profit Margin||2.95%|
How did AHX perform over the long term?See historical performance and comparison
2.2%Current Dividend Yield
Is AHX undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 2/6
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for AHX?
Other financial metrics that can be useful for relative valuation.
|What is AHX's n/a Ratio?|
Price to Earnings Ratio vs Peers
How does AHX's PE Ratio compare to its peers?
|AHX PE Ratio vs Peers|
|Company||PE||Estimated Growth||Market Cap|
SLA SILK Laser Australia
CAJ Capitol Health
IDX Integral Diagnostics
ACL Australian Clinical Labs
AHX Apiam Animal Health
Price-To-Earnings vs Peers: AHX is expensive based on its Price-To-Earnings Ratio (27.6x) compared to the peer average (23.9x).
Price to Earnings Ratio vs Industry
How does AHX's PE Ratio compare vs other companies in the Global Healthcare Industry?
Price-To-Earnings vs Industry: AHX is expensive based on its Price-To-Earnings Ratio (27.6x) compared to the Global Healthcare industry average (17.4x)
Price to Earnings Ratio vs Fair Ratio
What is AHX's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PE Ratio||27.6x|
|Fair PE Ratio||23.2x|
Price-To-Earnings vs Fair Ratio: AHX is expensive based on its Price-To-Earnings Ratio (27.6x) compared to the estimated Fair Price-To-Earnings Ratio (23.2x).
Share Price vs Fair Value
What is the Fair Price of AHX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: AHX (A$0.74) is trading below our estimate of fair value (A$1.61)
Significantly Below Fair Value: AHX is trading below fair value by more than 20%.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.
Discover undervalued companies
How is Apiam Animal Health forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
Future Growth Score3/6
Future Growth Score 3/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: AHX's forecast earnings growth (17.5% per year) is above the savings rate (1.8%).
Earnings vs Market: AHX's earnings (17.5% per year) are forecast to grow faster than the Australian market (6.7% per year).
High Growth Earnings: AHX's earnings are forecast to grow, but not significantly.
Revenue vs Market: AHX's revenue (8.2% per year) is forecast to grow faster than the Australian market (3.8% per year).
High Growth Revenue: AHX's revenue (8.2% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: AHX's Return on Equity is forecast to be low in 3 years time (9.2%).
Discover growth companies
How has Apiam Animal Health performed over the past 5 years?
Past Performance Score1/6
Past Performance Score 1/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: AHX has a large one-off loss of A$1.6M impacting its June 30 2022 financial results.
Growing Profit Margin: AHX's current net profit margins (3%) are lower than last year (4%).
Past Earnings Growth Analysis
Earnings Trend: AHX's earnings have grown by 6% per year over the past 5 years.
Accelerating Growth: AHX's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: AHX had negative earnings growth (-7.9%) over the past year, making it difficult to compare to the Healthcare industry average (-7.9%).
Return on Equity
High ROE: AHX's Return on Equity (4.2%) is considered low.
Discover strong past performing companies
How is Apiam Animal Health's financial position?
Financial Health Score5/6
Financial Health Score 5/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: AHX's short term assets (A$35.9M) exceed its short term liabilities (A$28.8M).
Long Term Liabilities: AHX's short term assets (A$35.9M) do not cover its long term liabilities (A$61.6M).
Debt to Equity History and Analysis
Debt Level: AHX's net debt to equity ratio (36.1%) is considered satisfactory.
Reducing Debt: AHX's debt to equity ratio has reduced from 44.6% to 38.7% over the past 5 years.
Debt Coverage: AHX's debt is well covered by operating cash flow (35.7%).
Interest Coverage: AHX's interest payments on its debt are well covered by EBIT (6.1x coverage).
Discover healthy companies
What is Apiam Animal Health current dividend yield, its reliability and sustainability?
Dividend Score 2/6
Cash Flow Coverage
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: AHX's dividend (2.18%) isn’t notable compared to the bottom 25% of dividend payers in the Australian market (2.77%).
High Dividend: AHX's dividend (2.18%) is low compared to the top 25% of dividend payers in the Australian market (6.8%).
Stability and Growth of Payments
Stable Dividend: AHX has been paying a dividend for less than 10 years and during this time payments have been volatile.
Growing Dividend: AHX has only been paying a dividend for 6 years, and since then payments have not increased.
Earnings Payout to Shareholders
Earnings Coverage: With its reasonably low payout ratio (46.8%), AHX's dividend payments are well covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: With its reasonably low cash payout ratio (26.3%), AHX's dividend payments are well covered by cash flows.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Dr. Christopher Irwin Richards, also known as Chris, BSc, BVSc, MAICD, has been Managing Director of Apiam Animal Health Limited since November 1, 2015. Dr. Richards founded Chris Richards & Associates in...
CEO Compensation Analysis
Compensation vs Market: Chris's total compensation ($USD334.97K) is about average for companies of similar size in the Australian market ($USD280.89K).
Compensation vs Earnings: Chris's compensation has been consistent with company performance over the past year.
Experienced Management: AHX's management team is considered experienced (2.7 years average tenure).
Experienced Board: AHX's board of directors are considered experienced (6.8 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: AHX insiders have sold more shares than they have bought in the past 3 months.
Recent Insider Transactions
|08 Sep 22||BuyAU$184,110||Christopher Richards||Individual||243,854||AU$0.76|
|06 Sep 22||BuyAU$11,464||Christopher Richards||Individual||14,512||AU$0.79|
|06 Sep 22||SellAU$354,317||Christopher Richards||Individual||458,366||AU$0.77|
|01 Sep 22||BuyAU$476,179||Regal Partners Limited||Company||602,759||AU$0.79|
|01 Sep 22||SellAU$476,179||Regal Partners Limited||Company||602,759||AU$0.79|
|24 Jun 22||BuyAU$34,347||Andrew Vizard||Individual||49,067||AU$0.70|
|24 Jun 22||BuyAU$496||Richard Dennis||Individual||709||AU$0.70|
|24 Jun 22||BuyAU$8,652||Jan Tennent||Individual||12,360||AU$0.70|
|03 Jun 22||BuyAU$4,507,193||Christopher Richards||Individual||6,438,846||AU$0.70|
|23 Mar 22||BuyAU$29,484||Christopher Richards||Individual||33,581||AU$0.88|
|02 Mar 22||SellAU$10,119||Richard Dennis||Individual||11,538||AU$0.88|
|01 Nov 21||BuyAU$95,963||Christopher Richards||Individual||101,142||AU$0.95|
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 29.6%.
|Ownership||Name||Shares||Current Value||Change %||Portfolio %|
Apiam Animal Health Limited's employee growth, exchange listings and data sources
- Name: Apiam Animal Health Limited
- Ticker: AHX
- Exchange: ASX
- Founded: 1998
- Industry: Health Care Services
- Sector: Healthcare
- Implied Market Cap: AU$128.222m
- Shares outstanding: 174.45m
- Website: https://www.apiam.com.au
Number of Employees
- Apiam Animal Health Limited
- 27-33 Piper Lane
- East Bendigo
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|AHX||ASX (Australian Securities Exchange)||Yes||Ordinary Shares||AU||AUD||Dec 2015|
|AHX||CHIA (Chi-X Australia)||Yes||Ordinary Shares||AU||AUD||Dec 2015|
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/09/23 00:00|
|End of Day Share Price||2022/09/23 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.